RxDoctor Payments Data

Yuri Nam, NP

Acute Care · San Francisco, CANPI 1942620778

Payments from drug & device makers

$2,940in general payments, 2019–2025

Across 22 payments — averaging $133.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$2K
  • Abbott$407
  • Alnylam Pharmaceuticals Inc.$234
  • Impulse Dynamics (USA) Inc.$171
  • Boehringer Ingelheim$125
  • Lexicon Pharmaceuticals, Inc.$125
  • plus $339 from 3 others

What the payments were for

  • Travel & lodging$98634%
  • Food & beverage$1,95566%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,940 in reported general payments places this provider in the 85th percentile of 1,153 acute care providers in California.

See all acute care providers in California

Medicare billing

Part B allowed, 2024
$70,754
Medicare patients
167
Services billed
1,027

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis145$3,316,514
EntrestoSacubitril/Valsartan337$499,312
JardianceEmpagliflozin174$234,016
FarxigaDapagliflozin Propanediol114$127,654
EliquisApixaban64$70,529
CorlanorIvabradine Hcl17$15,901
Bumetanide127$8,648
Eplerenone98$6,892
DapagliflozinDapagliflozin Propanediol11$5,238
Metoprolol Succinate161$3,228
Isosorbide Mononitrate ErIsosorbide Mononitrate75$3,175
Ranolazine ErRanolazine18$2,944
Potassium Chloride51$1,808
Spironolactone195$1,590
Isosorbide Dinitrate16$1,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$125$234,016174 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,153 acute care providers in California.

Other acute care in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →